Vice President and Head of Clinical Development
Dagna Laufer, M.D., oversees planning and implementation for clinical development of IAVI-sponsored vaccine candidates. Since 2008, Laufer has served in several key medical and clinical roles at IAVI, ensuring the safety and effectiveness of vaccine research.
Prior to joining IAVI, Laufer was Director, Clinical Viral Vaccines Research, at Wyeth, which conducted early phase prophylactic and therapeutic HIV clinical trials. She also led the Phase IV (post-licensure) team for the seven-valent pneumococcal conjugate vaccine (Prevnar®) as well as the Phase IV work internationally for vaccine products.
Laufer earned her M.D. at New York Medical College and her B.A. at Johns Hopkins University. She trained in pediatrics at St. Christopher’s Hospital for Children in Philadelphia and as a fellow in pediatric infectious diseases at Children’s Hospital of Philadelphia.